Site navigation

Navigation

Venous thromboembolism - rivaroxaban

Rivaroxaban for the prevention of venous thromboembolism

Status: History
Expected date of issue: April 2009
Wave: 17
Process: STA
Topic area:
  • Cardiovascular
 

NICE project team

Executive Lead: Gillian Leng
Technical Lead: David Chandiwana
Communications manager: Kristin O'Leary
Project manager: Bijal Chandarana
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 08 October 2008
1st appraisal committee meeting: 22 January 2009
Top


 

Consultees and Commentators

Consultees Commentators (no right to submit or appeal)

Manufacturers / Sponsors

  • Bayer Schering Pharma (rivaroxiban)

Patient / Carer Groups

  • Afiya Trust
  • Age Concern England
  • Anticoagulation Europe
  • Black Health Agency
  • British Ethnic Health Awareness Foundation (BEHAF)
  • British Lung Foundation
  • Chinese National Healthy Living Centre
  • Confederation of Indian Organisations
  • Counsel and Care
  • DVT Awareness Campaign
  • Equalities National Council
  • Help the Aged
  • Lifeblood: The Thrombosis Charity
  • Muslim Council of Great Britain
  • Muslim Health Network
  • South Asian Health Foundation
  • Specialised Healthcare Alliance

Professional Groups

  • Anticoagulation Specialist Association
  • Association of Surgeons of Great Britain and Ireland
  • British Association for Service to the Elderly
  • British Association for Surgery of the Knee
  • British Geriatrics Society
  • British Orthopaedic Association
  • British Society for Haematology
  • British Society for Haemostasis and Thrombosis
  • British Thoracic Society
  • Clinical Leaders of Thrombosis (CLOT)
  • Royal College of Anaesthetists
  • Royal College of General Practitioners
  • Royal College of Nursing
  • Royal College of Pathologists
  • Royal College of Physicians
  • Royal College of Surgeons
  • Royal Pharmaceutical Society
  • Royal Society of Medicine - Forum on Intellectual Disabilities
  • Society for Vascular Technology
  • Society for Vascular Ultrasound
  • Society of Vascular Nurses
  • United Kingdom Clinical Pharmacy Association
  • Vascular Society of Great Britain and Ireland

Others

  • Coventry PCT
  • Department of Health
  • Hammersmith and Fulham PCT
  • Welsh Assembly Government

General

  • Age Concern Cymru
  • Board of Community Health Councils in Wales
  • British National Formulary
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Medicines and Healthcare products Regulatory Agency
  • National Association for Primary Care
  • National Public Health Service for Wales
  • NHS Alliance
  • NHS Confederation
  • NHS Purchasing and Supply Agency
  • NHS Quality Improvement Scotland
  • Scottish Medicines Consortium

Comparator manufacturer(s)

  • Amdipharm (bemiparin sodium)
  • GlaxoSmithKline (fondaparinux sodium)
  • Leo Laboratories (tinzaparin sodium)
  • Pfizer (dalteparin sodium)
  • Sanofi-Aventis (enoxaparin sodium)
  • Boehringer Ingelheim Ltd

Relevant research groups

  • Antithrombotic Trialists' (ATT) Collaboration
  • Cochrane Peripheral Vascular Disease Group
  • Policy Research Institute on Ageing and Ethnicity
  • Research Institute for the Care of the Elderly
  • Thrombosis Research Institute

Evidence Review Group

  • School of Health & Related Research Sheffield (ScHARR)
  • National Coordinating Centre for Health Technology Assessment

Associated Guideline Groups

  • National Collaborating Centre for Acute Care

Associated Public Health Groups

  • None

Top


 

Key documents

This page was last updated:   21 October 2008